Stock Analysis: PharmaEssentia
Company: PharmaEssentia Corporation
Bloomberg ticker: 6446 TT
Market cap: US$6,191m
Background: PharmaEssentia Corporation develops and distributes drugs to treat hepatitis, chronic myeloid leukemia, essential thrombocythemia, myeloid fibrosis, polycythemia vera, hepatitis, and cancer. The company was founded in 2003 by a group of Taiwanese-American executives and scientists from American biotech and pharmaceutical companies.
World Class Benchmarking of PharmaEssentia Corp
(Click on image to enlarge)
- Profitable Growth rank of 1 was same compared to the prior period’s 1st rank
- This is World Class performance compared to 310 medium Health Care companies worldwide
- Profitability rank of 1 was the same as its Growth rank of 1
- Profitability rank of 1 was up compared to the prior period’s 3rd rank
- This is World Class performance compared to peers
- Growth rank of 1 was the same compared to the prior period’s 1st rank
- This is World Class performance compared to peers
More By This Author:
Stock Analysis: MeiHua Holdings Group
Stock Analysis: Bukalapak.com
Stock Analysis: Siam Cement
Disclaimer: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and ...
more
